Secarna Pharmaceuticals GmbH & Co. KG

© IZB Innovations- und Gründerzentrum Biotechnologie

Secarna Pharmaceuticals is the leading independent European antisense oligonucleotide (ASO) drug discovery and development company. Secarna’s mission is to leverage its proprietary LNAplus™ antisense oligonucleotide discovery platform to discover, research and develop highly specific, safe, and efficacious antisense therapies for indications in which antisense-based approaches have clear benefits over other therapeutic approaches. Combining technical excellence with antisense drug discovery and development expertise and a global network of highly recognized KOLs, Secarna is paving the path for a new generation of ASO therapeutics.

Secarna Pharmaceuticals at a glance:


Field of Activity Discovery and development of highly specific, safety-optimized and efficacious third-generation ASOs, an area that is enjoying strong tailwinds as evidenced by recent market approvals and high value partnering transactions. With in-house programs up to preclinical proof-of-concept and in partnerships with pharma and biotech companies, Secarna is addressing high unmet medical needs in the areas of oncology/immuno-oncology, immunology, as well as inflammatory, fibrotic, neurodegenerative and cardiometabolic diseases and has built a rich, multifaceted pipeline of innovative ASO therapies in various stages of pre-clinical development.
Ownership Structure and Financing Privately held.
Partners Secarna’s LNAplusTM platform and ASOs have been validated by in-house projects and in collaborations with top tier industry as well as academic partners. Recent partnerships include Denali Therapeutics Inc. and Lipigon Pharmaceuticals AB. Within a strategic partnership with Evotec SE, the companies are progressing towards the establishment of a pipeline of co-owned antisense oligonucleotide therapies.
Unique Selling Point Secarna’s proprietary 3rd generation ASO platform LNAplusTM – the only independent ASO platform – encompasses all aspects of drug discovery and pre-clinical development. It has proven to be fast, reliable, scalable, efficient and to provide for a uniquely integrated workflow. The platform includes the powerful proprietary OligofyerTM bioinformatics and LNA Vit(r)oxTM screening system, best-in-class high throughput screening, and target-specific functional assays. With that, the Company seeks to establish ASO therapeutics as the third pillar in drug development next to small molecules and antibodies and to expand the universe of druggable targets.
Date of Incorporation/Number of Employees 2015/15



Alexander Gebauer, MD, PhD, CEO & Managing Director
Christian Pangratz, Managing Director


Address Am Klopferspitz 19
82152 Planegg/Martinsried
Telephone +49 89 215 46 375/ 385
Social Media LinkedIn